Analytical Data
-
基因名
PIAS4
- Application
-
别名
PIAS4；PIASG；E3 SUMO-Protein ligase PIAS4
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q8N2W9
-
表达区间
2-510aa
-
氨基酸序列
AAELVEAKN MVMSFRVSDL QMLLGFVGRS KSGLKHELVT RALQLVQFDC SPELFKKIKE LYETRYAKKN SEPAPQPHRP LDPLTMHSTY DRAGAVPRTP LAGPNIDYPV LYGKYLNGLG RLPAKTLKPE VRLVKLPFFN MLDELLKPTE LVPQNNEKLQ ESPCIFALTP RQVELIRNSR ELQPGVKAVQ VVLRICYSDT SCPQEDQYPP NIAVKVNHSY CSVPGYYPSN KPGVEPKRPC RPINLTHLMY LSSATNRITV TWGNYGKSYS VALYLVRQLT SSELLQRLKT IGVKHPELCK ALVKEKLRLD PDSEIATTGV RVSLICPLVK MRLSVPCRAE TCAHLQCFDA VFYLQMNEKK PTWMCPVCDK PAPYDQLIID GLLSKILSEC EDADEIEYLV DGSWCPIRAE KERSCSPQGA ILVLGPSDAN GLLPAPSVNG SGALGSTGGG GPVGSMENGK PGADVVDLTL DSSSSSEDEE EEEEEEEDED EEGPRPKRRC PFQKGLVPAC
-
分子量
56 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PIAS4 (Protein Inhibitor of Activated STAT4) is a member of the PIAS (Protein Inhibitor of Activated STAT) family, which plays a crucial role in modulating the activity of Signal Transducer and Activator of Transcription (STAT) proteins. These proteins are key players in various signaling pathways, particularly in the immune response and inflammatory processes. Aberrant STAT signaling is implicated in various diseases, including cancer and autoimmune disorders. Research into PIAS4 has garnered attention due to its potential as a therapeutic target. Specifically, PIAS4 acts as a negative regulator, inhibiting the activation of STAT4, which in turn can influence immune cell function and survival. Understanding the structure and function of PIAS4 at the molecular level is critical for deciphering its regulatory mechanisms. Recent studies have explored its interactions with other proteins and its role in post-translational modifications, revealing insights into its function in various cellular contexts. Additionally, the characterization of PIAS4-restructured proteins may lead to novel strategies for modulating immune responses, thereby providing avenues for clinical interventions in diseases linked to dysregulated STAT signaling. As the landscape of immunotherapy continues to evolve, PIAS4's regulatory role in immune responses positions it as an essential component for further research and potential drug development.
